financetom
Business
financetom
/
Business
/
Dominion Energy Maintains Outlook As Regulated Segments Drive Growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dominion Energy Maintains Outlook As Regulated Segments Drive Growth
Aug 1, 2025 10:09 AM

Dominion Energy Inc. ( D ) on Friday announced second-quarter financial results, net income of $760 million, or 88 cents per share, a significant increase from $563 million, or 64 cents per share, in the same period of 2024

The company reported adjusted earnings per share of 75 cents, which beat the consensus estimate of 72 cents.

Operating revenue for the quarter increased 9.3% year-over-year to $3.81 billion; however, it fell short of the $3.86 billion estimate.

Also Read: Exxon Mobil Hits Record Production, CEO Reaffirms Hunt For Value-Driven Deals

Dominion Energy’s regulated business segments were the primary drivers of growth for the quarter. Adjusted operating earnings for Dominion Energy Virginia rose to $549 million, up from $485 million in the same period last year.

Dominion Energy South Carolina also saw a significant increase, with adjusted operating earnings climbing to $109 million from $69 million a year ago.

The Contracted Energy segment experienced a decline in adjusted operating earnings, falling to $47 million from $100 million in the prior-year quarter due to planned outages at the Millstone power station.

Outlook

Dominion Energy ( D ) affirmed its full-year 2025 adjusted earnings guidance range of $3.28 to $3.52 per share, consistent with the consensus estimate of $3.39.

Price Action: D shares are trading higher by 3.49% to $60.49 at Friday’s last check.

Read Next:

LyondellBasell Defers Projects, Optimizes Portfolio To Weather Extended Cyclical Downturn

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Former top lawyers at major companies decry Trump orders against law firms
Former top lawyers at major companies decry Trump orders against law firms
Apr 8, 2025
* 67 current and former general counsels submit legal brief * Filing backs Perkins Coie in lawsuit against Trump administration * Trump orders 'hijack' companies' ability to choose lawyers, brief says By David Thomas, Mike Scarcella and Sara Merken April 8 (Reuters) - Former top legal executives at large companies including Microsoft ( MSFT ), Intel ( INTC ) and...
FBI looking into Tesla Supercharger damage incident, latest in series of vandalism acts
FBI looking into Tesla Supercharger damage incident, latest in series of vandalism acts
Apr 8, 2025
April 8 (Reuters) - The Federal Bureau of Investigation said it was looking into an incident that left a Tesla Supercharger station damaged in a city in Washington in the wee hours of Tuesday. Electrek first reported the incident, saying an explosion led to a temporary shutdown of the charging station. Reuters could not independently verify if there was an...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly
Apr 8, 2025
NEW YORK, April 8 (Reuters) - Bristol Myers Squibb ( BMY ) won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its blockbuster blood cancer drug Pomalyst, keeping cheaper generic versions off the market. In a 70-page decision made public on Tuesday, U.S. District...
Copyright 2023-2026 - www.financetom.com All Rights Reserved